243 related articles for article (PubMed ID: 23920379)
1. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
[TBL] [Abstract][Full Text] [Related]
2. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T; Lai R; Veillard AS; Paris E; Soria JC; Rosell R; Taron M; Graziano S; Kratzke R; Seymour L; Shepherd FA; Pignon JP; Sève P
Ann Oncol; 2012 Jan; 23(1):86-93. PubMed ID: 21471564
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
Graziano SL; Gu L; Wang X; Tatum AH; Vollmer RT; Strauss GM; Kratzke R; Dudek AZ; Vokes EE; Green MR; ; ;
J Thorac Oncol; 2010 Jun; 5(6):810-7. PubMed ID: 20521348
[TBL] [Abstract][Full Text] [Related]
4. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.
Tsao MS; Marguet S; Le Teuff G; Lantuejoul S; Shepherd FA; Seymour L; Kratzke R; Graziano SL; Popper HH; Rosell R; Douillard JY; Le-Chevalier T; Pignon JP; Soria JC; Brambilla EM
J Clin Oncol; 2015 Oct; 33(30):3439-46. PubMed ID: 25918286
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
8. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
13. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
[TBL] [Abstract][Full Text] [Related]
17. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.
Seymour L; Le Teuff G; Brambilla E; Shepherd FA; Soria JC; Kratzke R; Graziano S; Douillard JY; Rosell R; Reiman A; Lacas B; Lueza B; Aviel-Ronen S; McLeer A; Le Chevalier T; Pirker R; Filipits M; Dunant A; Pignon JP; Tsao MS;
Clin Lung Cancer; 2019 Mar; 20(2):66-73.e6. PubMed ID: 30414783
[TBL] [Abstract][Full Text] [Related]
18. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
Brambilla E; Le Teuff G; Marguet S; Lantuejoul S; Dunant A; Graziano S; Pirker R; Douillard JY; Le Chevalier T; Filipits M; Rosell R; Kratzke R; Popper H; Soria JC; Shepherd FA; Seymour L; Tsao MS
J Clin Oncol; 2016 Apr; 34(11):1223-30. PubMed ID: 26834066
[TBL] [Abstract][Full Text] [Related]
20. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X; Rousseau V; Sun H; Lantuejoul S; Filipits M; Pirker R; Popper H; Mendiboure J; Vataire AL; Le Chevalier T; Soria JC; Brambilla E; Dunant A; Hainaut P;
Mol Oncol; 2014 May; 8(3):555-64. PubMed ID: 24495481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
